XML 57 R46.htm IDEA: XBRL DOCUMENT
v3.21.2

Intangible Assets (Details Narrative) - USD ($) |  | 3 Months Ended | 6 Months Ended | 9 Months Ended | 12 Months Ended |
--- | --- | --- | --- | --- | --- | ---
Sep. 30, 2020 | Sep. 30, 2021 | Sep. 30, 2020 | Jun. 30, 2021 | Sep. 30, 2021 | Sep. 30, 2020 | Dec. 31, 2019 | Dec. 31, 2018 | Dec. 31, 2020
Restructuring Cost and Reserve [Line Items] |  |  |  |  |  |  |  |  |
Finite-Lived Intangible Assets, Net |  |  |  |  |  |  |  |  | $ 113,660
2018 Aspire Purchase Agreements [Member] |  |  |  |  |  |  |  |  |
Restructuring Cost and Reserve [Line Items] |  |  |  |  |  |  |  |  |
Finite-Lived Intangible Assets, Net |  |  |  |  |  |  |  |  | 113,660
Finite-Lived Intangible Assets, Accumulated Amortization |  |  |  |  |  |  |  |  | $ 1,477,554
Glioblastoma Multiforme Brain Cancer [Member] |  |  |  |  |  |  |  |  |
Restructuring Cost and Reserve [Line Items] |  |  |  |  |  |  |  |  |
Asset Impairment Charges |  |  |  |  |  |  | $ 2,400,000 |  |
IPR and D Drug Technology Platforms [Member] |  |  |  |  |  |  |  |  |
Restructuring Cost and Reserve [Line Items] |  |  |  |  |  |  |  |  |
Asset Impairment Charges |  | $ 0 | $ 0 |  | 0 | $ 0 |  |  |
IPR and D Drug Technology Platforms [Member] | Ovarian Cancer [Member] |  |  |  |  |  |  |  |  |
Restructuring Cost and Reserve [Line Items] |  |  |  |  |  |  |  |  |
Finite-lived Intangible Assets Acquired |  |  |  |  | 13,300,000 |  |  |  |
EGEN Inc [Member] |  |  |  |  |  |  |  |  |
Restructuring Cost and Reserve [Line Items] |  |  |  |  |  |  |  |  |
Asset Impairment Charges |  |  |  |  |  |  |  | $ 7,000,000 |
Goodwill, Acquired During Period |  |  |  |  | 2,000,000.0 |  |  |  |
EGEN Inc [Member] | Purchase Agreement [Member] |  |  |  |  |  |  |  |  |
Restructuring Cost and Reserve [Line Items] |  |  |  |  |  |  |  |  |
Finite-lived Intangible Assets Acquired |  |  |  |  | $ 1,600,000 |  |  |  |
Finite-Lived Intangible Asset, Useful Life |  |  |  |  | 7 years |  |  |  |
Amortization |  |  | 56,830 | $ 113,660 |  | $ 170,487 |  |  |
EGEN Inc [Member] | Glioblastoma Multiforme Brain Cancer [Member] |  |  |  |  |  |  |  |  |
Restructuring Cost and Reserve [Line Items] |  |  |  |  |  |  |  |  |
Asset Impairment Charges | $ 2,400,000 |  |  |  |  |  |  | $ 9,400,000 |
Noncash Charge |  |  | $ 2,400,000 |  |  |  |  |  |
EGEN Inc [Member] | IPR and D Drug Technology Platforms [Member] |  |  |  |  |  |  |  |  |
Restructuring Cost and Reserve [Line Items] |  |  |  |  |  |  |  |  |
Indefinite-lived Intangible Assets Acquired |  |  |  |  | $ 24,200,000 |  |  |  |

X
- Definition Non-cash charge. + References No definition available. + Details
Name: | CLSN_NoncashCharge
Namespace Prefix: | CLSN_
Data Type: | xbrli:monetaryItemType
Balance Type: | debit
Period Type: | duration

X
- Definition The aggregate amount of recurring noncash expense charged against earnings in the period to allocate the cost of assets over their estimated remaining economic lives. + References Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef -Publisher FASB -Name Accounting Standards Codification -Topic 350 -SubTopic 30 -Section 50 -Paragraph 2 -Subparagraph (a)(2) -URI http://asc.fasb.org/extlink&oid=66006027&loc=d3e16323-109275 Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef -Publisher FASB -Name Accounting Standards Codification -Topic 230 -SubTopic 10 -Section 45 -Paragraph 28 -Subparagraph (b) -URI http://asc.fasb.org/extlink&oid=123570139&loc=d3e3602-108585 + Details
Name: | us-gaap_AdjustmentForAmortization
Namespace Prefix: | us-gaap_
Data Type: | xbrli:monetaryItemType
Balance Type: | debit
Period Type: | duration

X
- Definition Amount of write-down of assets recognized in the income statement. Includes, but is not limited to, losses from tangible assets, intangible assets and goodwill. + References Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef -Publisher FASB -Name Accounting Standards Codification -Topic 230 -SubTopic 10 -Section 45 -Paragraph 28 -Subparagraph (b) -URI http://asc.fasb.org/extlink&oid=123570139&loc=d3e3602-108585 Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef -Publisher FASB -Name Accounting Standards Codification -Topic 360 -SubTopic 10 -Section 45 -Paragraph 4 -URI http://asc.fasb.org/extlink&oid=123351718&loc=d3e2420-110228 + Details
Name: | us-gaap_AssetImpairmentCharges
Namespace Prefix: | us-gaap_
Data Type: | xbrli:monetaryItemType
Balance Type: | debit
Period Type: | duration

X
- Definition Useful life of finite-lived intangible assets, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents the reported fact of one year, five months, and thirteen days. + References No definition available. + Details
Name: | us-gaap_FiniteLivedIntangibleAssetUsefulLife
Namespace Prefix: | us-gaap_
Data Type: | xbrli:durationItemType
Balance Type: | na
Period Type: | duration

X
- Definition Accumulated amount of amortization of assets, excluding financial assets and goodwill, lacking physical substance with a finite life. + References Reference 1: http://www.xbrl.org/2003/role/disclosureRef -Publisher FASB -Name Accounting Standards Codification -Topic 350 -SubTopic 30 -Section 50 -Paragraph 2 -Subparagraph (a)(1) -URI http://asc.fasb.org/extlink&oid=66006027&loc=d3e16323-109275 + Details
Name: | us-gaap_FiniteLivedIntangibleAssetsAccumulatedAmortization
Namespace Prefix: | us-gaap_
Data Type: | xbrli:monetaryItemType
Balance Type: | credit
Period Type: | instant

X
- Definition Amount after amortization of assets, excluding financial assets and goodwill, lacking physical substance with a finite life. + References Reference 1: http://www.xbrl.org/2003/role/disclosureRef -Publisher FASB -Name Accounting Standards Codification -Topic 926 -SubTopic 20 -Section 50 -Paragraph 5 -URI http://asc.fasb.org/extlink&oid=120154696&loc=d3e54445-107959 Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef -Publisher FASB -Name Accounting Standards Codification -Topic 350 -SubTopic 30 -Section 50 -Paragraph 2 -Subparagraph (a)(1) -URI http://asc.fasb.org/extlink&oid=66006027&loc=d3e16323-109275 + Details
Name: | us-gaap_FiniteLivedIntangibleAssetsNet
Namespace Prefix: | us-gaap_
Data Type: | xbrli:monetaryItemType
Balance Type: | debit
Period Type: | instant

X
- Definition Amount of increase in assets, excluding financial assets, lacking physical substance with a definite life, from an acquisition. + References Reference 1: http://www.xbrl.org/2003/role/disclosureRef -Publisher FASB -Name Accounting Standards Codification -Topic 350 -SubTopic 30 -Section 50 -Paragraph 1 -Subparagraph (a)(1) -URI http://asc.fasb.org/extlink&oid=66006027&loc=d3e16265-109275 + Details
Name: | us-gaap_FinitelivedIntangibleAssetsAcquired1
Namespace Prefix: | us-gaap_
Data Type: | xbrli:monetaryItemType
Balance Type: | debit
Period Type: | duration

X
- Definition Amount of increase in asset representing future economic benefits arising from other assets acquired in a business combination that are not individually identified and separately recognized resulting from a business combination. + References Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef -Publisher FASB -Name Accounting Standards Codification -Topic 350 -SubTopic 20 -Section 50 -Paragraph 1 -Subparagraph (b) -URI http://asc.fasb.org/extlink&oid=121556970&loc=d3e13816-109267 + Details
Name: | us-gaap_GoodwillAcquiredDuringPeriod
Namespace Prefix: | us-gaap_
Data Type: | xbrli:monetaryItemType
Balance Type: | debit
Period Type: | duration

X
- Definition Amount of increase in assets, excluding financial assets and goodwill, lacking physical substance with an indefinite life, from an acquisition. + References No definition available. + Details
Name: | us-gaap_IndefinitelivedIntangibleAssetsAcquired
Namespace Prefix: | us-gaap_
Data Type: | xbrli:monetaryItemType
Balance Type: | debit
Period Type: | duration

X
- Definition Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table. + References No definition available. + Details
Name: | us-gaap_RestructuringCostAndReserveLineItems
Namespace Prefix: | us-gaap_
Data Type: | xbrli:stringItemType
Balance Type: | na
Period Type: | duration

X
- Details
Name: | us-gaap_TypeOfArrangementAxis=CLSN_AspirePurchaseAgreementsMember
Namespace Prefix: |
Data Type: | na
Balance Type: |
Period Type: |

X
- Details
Name: | us-gaap_ContingentConsiderationByTypeAxis=CLSN_GlioblastomaMultiformeBrainCancerMember
Namespace Prefix: |
Data Type: | na
Balance Type: |
Period Type: |

X
- Details
Name: | dei_LegalEntityAxis=CLSN_IPRAndDDrugTechnologyPlatformsMember
Namespace Prefix: |
Data Type: | na
Balance Type: |
Period Type: |

X
- Details
Name: | us-gaap_ContingentConsiderationByTypeAxis=CLSN_OvarianCancerMember
Namespace Prefix: |
Data Type: | na
Balance Type: |
Period Type: |

X
- Details
Name: | us-gaap_BusinessAcquisitionAxis=CLSN_EGENIncMember
Namespace Prefix: |
Data Type: | na
Balance Type: |
Period Type: |

X
- Details
Name: | us-gaap_TypeOfArrangementAxis=CLSN_PurchaseAgreementMember
Namespace Prefix: |
Data Type: | na
Balance Type: |
Period Type: |